

Use of 18F-fluorodeoxyglucose Positron Emission Tomography and other biomarkers to assess risk of clinical progression in patients with amnesic mild cognitive impairment

M. Sagrario Manzano¹, D.A. Perez Martinez², S. Muñiz Castrillo³, P. Garrido Jimenez⁴, B. Anaya Caravaca⁵, M. Angeles Balsa Breton⁶, J.A Blanco Cabello⁷, J. Iglesias⁸

¹Neurology, Infanta Leonor Hospital, Spain

²Neurology, 12 de Octubre Hospital, Spain

³Neurology, Infanta Cristina Hospital, Spain

⁴Neurology, Medicine Student, Infanta Cristina Hospital, Spain

⁵Neuropsychologist, Infanta Cristina Hospital, Spain

⁶Nuclear Medicine Department, Getafe Hospital, Spain

⁷Neuro-radiologist, Infanta Cristina Hospital, Spain

⁸Freelance, Big Data Analyst, Spain